Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zbtb12 siRNA
- Development stage
- Preclinical
- Lead developer
- Peking University First Hospital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Zbtb12 siRNA is a preclinical small interfering RNA (siRNA) therapeutic candidate designed to target and silence the zinc finger and BTB domain containing 12 (ZBTB12) gene. Developed by researchers at Peking University First Hospital, this siRNA is conjugated with lithocholic acid to achieve targeted delivery to renal tubular epithelial cells. ZBTB12 acts as a transcriptional repressor of translocase of outer mitochondrial membrane 7 (TOMM7). By silencing ZBTB12, the siRNA upregulates TOMM7 expression, which in turn restores PINK1/Parkin-mediated mitophagy and alleviates renal tubular injury. It is being investigated as a potential treatment strategy for diabetic kidney disease (DKD).
- Other names
- ZBTB12 siRNAZBTB-12 siRNAZBTB 12 siRNAZbtb12 small interfering RNAZbtb-12 small interfering RNAZbtb 12 small interfering RNAlithocholic acid-conjugated Zbtb12 siRNA
Beyond the preview
Go deeper on Zbtb12 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zbtb12 siRNA.